（文章来源：证券日报） 证券日报网讯 12月8日，乐心医疗在互动平台回答投资者提问时表示，公司拥有多维度体征健康监测产 品线，包括主营产品：智能电子血压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备 以及手环手表等，前述产品为公司主要收入来源；近年推出的产品OTC助听器和十二导联智能心电衣 （通过参股公司布局）正逐步实现商业落地（其未来对公司业绩的影响公司尚无法预判，请注意投资风 险）。公司的医疗级智能戒指目前在持续筹备优化中，尚未正式发布，该产品相对现有手表手环从功能 侧而言，在血氧、睡眠、心率、运动等基本监测功能外，还提供心血管状态的监测与评估，从外形来说 更加便携精巧、佩戴舒适；（公司曾在2019年推出医疗级心电手表LifesenseHealthWatchH1，未曾发布 H2）。 ...

Group 1 - Core viewpoint: 乐心医疗 has received approval for the renewal of its electronic blood pressure monitor medical device registration from the Guangdong Provincial Drug Administration [1] - Revenue composition for 乐心医疗 in the first half of 2025: home medical products account for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness trackers for 1.99% [1] - Current market capitalization of 乐心医疗 is 3 billion yuan [1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 乐心医疗回复：尊敬的投资者您好！公司拥有多维度体征健康监测产品线，包括主营产品：智能电子血 压计、电子健康秤、智能血糖监测产品、脂肪测量仪、心电监测设备以及手环手表等，前述产品为公司 主要收入来源；近年推出的产品OTC助听器和十二导联智能心电衣（通过参股公司布局）正逐步实现商 业落地（其未来对公司业绩的影响公司尚无法预判，请注意投资风险）。公司的医疗级智能戒指目前在 持续筹备优化中，尚未正式发布，该产品相对现有手表手环从功能侧而言，在血氧、睡眠、心率、运动 等基本监测功能外，还提供心血管状态的监测与评估，从外形来说更加便携精巧、佩戴舒适；（公司曾 在2019年推出医疗级心电手表Lifesense Health Watch H1，未曾发布H2）；感谢您的关注，祝您投资顺 利，谢谢。 证券之星消息，乐心医疗(300562)12月08日在投资者关系平台上答复投资者关心的问题。 投资者提问：领导好，请问公司核心产品:十二导联智能心电衣（iSENSE系列）， Nova智听OTC助听 器，医疗级智 ...

Company Overview - Le Xin Medical (SZ 300562) announced that as of the date of the announcement, Pan Weichao has pledged a total of 29.71 million shares, accounting for 44.47% of his total shareholding [1] Revenue Composition - For the first half of 2025, Le Xin Medical's revenue composition is as follows: home medical products account for 66.29%, electronic health scales account for 24.17%, other products account for 7.55%, and wearable fitness bands account for 1.99% [1] Market Capitalization - As of the report, Le Xin Medical has a market capitalization of 3.1 billion yuan [1]

Group 1 - The core point of the article is that 乐心医疗 (Lifesense Medical) held its seventh board meeting on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the first half of 2025, the revenue composition of 乐心医疗 is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - As of the time of reporting, 乐心医疗 has a market capitalization of 3.1 billion yuan [1]

Group 1 - The core point of the article is that 乐心医疗 (Lixun Medical) held its fifth board meeting on October 9, 2025, to discuss the stock option incentive plan for its employees [1] - For the first half of 2025, the revenue composition of 乐心医疗 is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - As of the report date, 乐心医疗 has a market capitalization of 3.1 billion yuan [1]

Group 1 - The core point of the news is the resignation of Huang Linxiang as the employee representative director and CFO of Le Xin Medical due to personal reasons, and the appointment of Wu Rong as the new CFO [1] - Le Xin Medical's revenue composition for the first half of 2025 is as follows: home medical products account for 66.29%, electronic health scales account for 24.17%, other products account for 7.55%, and wearable sports wristbands account for 1.99% [1] - As of the report date, Le Xin Medical has a market capitalization of 3.2 billion yuan [1] Group 2 - Related news includes the resignation of Yi Bingmin from Gao Le Co. as CFO and Vice General Manager [2] - Zhao Bin's resignation as Vice President and CFO of Yingxin Development is also noted [2] - Chen Feng Technology has appointed Dong Jianzao as the new CFO [2]

Company Changes - Huang Linxiang resigned from her positions as employee representative director and CFO due to personal reasons, and will no longer hold any positions in the company or its subsidiaries [1] - Wu Rong has been appointed as the new CFO after being nominated by the general manager and approved by the board's nomination and audit committees [1] Financial Performance - For the first half of 2025, the revenue composition of the company is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - The current market capitalization of the company is 3.2 billion yuan [1]

Group 1 - The core point of the news is that 乐心医疗 (Lixun Medical) announced a board meeting to discuss the authorization of a stock option incentive plan for 2025 [1] - For the first half of 2025, the revenue composition of 乐心医疗 is as follows: home medical products account for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - As of the report, 乐心医疗 has a market capitalization of 3.2 billion yuan [1]

Group 1 - The core point of the article is that 乐心医疗 (Lixun Medical) held its fifth board meeting on August 29, 2025, to discuss adjustments to its fundraising investment projects and extensions [1] - For the first half of 2025, the revenue composition of 乐心医疗 is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - As of the report date, 乐心医疗 has a market capitalization of 3.3 billion yuan [1]